What is VYNE Therapeutics Inc.'s current stock price?

VYNE Therapeutics Inc. (VYNE) currently trades at USD 28.56. Track real-time price changes and historical performance on AllInvestView.

What is VYNE Therapeutics Inc.'s dividend yield?

VYNE Therapeutics Inc. has a dividend yield of 70.45200000%. Track dividend payments and income with AllInvestView.

What sector is VYNE Therapeutics Inc. in?

VYNE Therapeutics Inc. operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

VYNE Therapeutics Inc. VYNE · Stock Open VYNE Therapeutics Inc. in new tab

28.56 USD

Add to portfolio

P/E

0.81

EPS

-27.58

Yield

70.45%

Safety Score

P/B

0.77

ROE

-63.16

Beta

2.01

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for VYNE Therapeutics Inc. (VYNE)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

VYNE Therapeutics Inc. Analysis (VYNE)

United States Health Care Official Website Stock

Is VYNE Therapeutics Inc. a good investment? VYNE Therapeutics Inc. (VYNE) is currently trading at 28.56 USD.

In terms of valuation, the stock trades at a P/E ratio of 0.81. This relatively low multiple may signal that VYNE Therapeutics Inc. is undervalued compared to historical market norms.

Earnings Schedule: VYNE Therapeutics Inc. is expected to release its next earnings report on Aug. 13, 2026. The market consensus estimate for Forward EPS is -82.50.

For income investors, VYNE Therapeutics Inc. pays a dividend yield of 70.45%.

Investor FAQ

Does VYNE Therapeutics Inc. pay a dividend?

Yes, it pays an annual dividend of 20.12 USD (70.45% yield).

What asset class is VYNE Therapeutics Inc.?

VYNE Therapeutics Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 13, 2026. The company currently has a trailing EPS of -27.58.

Company Profile

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.

Exchange Ticker

NMS (United States) VYNE

Trades

Dividend Yield

70.45%

Annual Dividends

20.12USD

Next Ex. Div Date

July 24, 2026

Dividend History paid per year (USD)

Historical Dividends

Year	Total Dividends
▸2026	0.40 USD
July 24, 2026	0.4024

Upcoming Dividends

Name	Payment Date	Status	Amount
VYNE Therapeutics Inc.	Jul 24, 2026	Paid	0.40242 USD

Stock Splits

Split Date	Split Ratio to 1
Feb. 16, 2021	0.250000
Feb. 13, 2023	0.060000
July 27, 2026	0.020000

VYNE Therapeutics Inc. VYNE · Stock Open VYNE Therapeutics Inc. in new tab

Key Metrics

Growth

Estimates

Dividend

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

VYNE Therapeutics Inc. Analysis (VYNE)

Investor FAQ

Company Profile

Fundamentals

Under Construction

VYNE Therapeutics Inc. VYNE · Stock Open VYNE Therapeutics Inc. in new tab

Key Metrics

Growth

Estimates

Dividend

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

VYNE Therapeutics Inc. Analysis (VYNE)

Investor FAQ

Company Profile

Explore Premium Features

Fundamentals

Under Construction

Community Discussion

Notifications